Preclinical data posters presented at EHA Congress

AI SummaryClose X

Poolbeg Pharma PLC announced new preclinical data for its POLB 001 drug candidate at the European Hematology Association Congress. The research indicates POLB 001's potential to prevent cytokine release syndrome (CRS) by reducing key inflammatory cytokines without impairing tumor cell death, and also suggests a new indication for POLB 001 in improving outcomes for elderly Acute Myeloid Leukemia (AML) patients when combined with Azacitidine. These findings reinforce POLB 001's utility as a preventative therapy for cancer immunotherapy-induced CRS and highlight its potential to enhance AML treatment efficacy.

Disclaimer*

UK 100

Latest directors dealings